{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-25-000800","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.760362+00:00","generated_at":"2026-05-21T09:47:44.890599+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"TOI Q1 revenue $104.4M (+10.3% YoY); net loss $19.6M vs $19.9M; reaffirms FY2025 guidance","bullets":["Revenue $104.4M, up 10.3% YoY from $94.7M; gross profit $17.2M, up 44.1%.","Net loss $19.6M ($0.21/share) vs $19.9M ($0.22) prior year; Adjusted EBITDA -$5.1M vs -$10.9M.","Pharmacy & Dispensary segment revenue $49.3M, gross profit >$9M, grew >20% YoY; FFS growth 9% QoQ.","Added >100,000 capitated lives in Q1; new contracts in FL, NV, CA; fully-delegated agreement started March 1 in FL.","Closed $16.5M private placement; exchanged $4.1M convertible notes for preferred stock & warrants; cash $39.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-25-000800","json":"https://secwatch.observer/filing/0001079973-25-000800.json","markdown":"https://secwatch.observer/filing/0001079973-25-000800.md","text":"https://secwatch.observer/filing/0001079973-25-000800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325000800/0001079973-25-000800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325000800/toi_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:47:44.890599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}